ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 96,526 shares, a growth of 315.4% from the June 15th total of 23,236 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily volume of 40,529 shares, the short-interest ratio is presently 2.4 days.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Fulcrum Equity Management purchased a new stake in ALPS Medical Breakthroughs ETF during the second quarter worth $263,000. Harbor Investment Advisory LLC purchased a new stake in ALPS Medical Breakthroughs ETF during the 2nd quarter worth approximately $29,000. Bank of America Corp DE raised its stake in ALPS Medical Breakthroughs ETF by 63.1% in the 1st quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock valued at $5,165,000 after purchasing an additional 38,193 shares during the last quarter. Independent Financial Group LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the first quarter valued at about $283,000. Finally, Sterling Investment Advisors Ltd. boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 50.1% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 22,025 shares of the company’s stock worth $1,153,000 after purchasing an additional 7,350 shares during the last quarter.
ALPS Medical Breakthroughs ETF Stock Performance
Shares of SBIO stock traded up $0.03 on Tuesday, hitting $65.36. The company had a trading volume of 22,351 shares, compared to its average volume of 37,490. The company has a 50-day moving average price of $56.84 and a 200-day moving average price of $53.61. ALPS Medical Breakthroughs ETF has a twelve month low of $32.21 and a twelve month high of $69.34.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Featured Stories
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
- 3 Energy Stocks Racing to Fix AI’s Power Problem
- No Space For Panic: T-Mobile Shrugs Off The Starlink Threat
- Prepare for the Next Wave of Factory Automation With These 3 Standout Names
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
